Characteristics of molecular subtypes and cinical outcomes in the immunotherapy Queue of extensive-stage small cell lung cancer patients
Jianan Li,Wentao Zhang,Yi Zhao,Jixian Li,Yuanliu Nie,Alei Feng,Qiang Li,Fengge Zhou,Renya Zeng,Zhe Yang
DOI: https://doi.org/10.1186/s12890-024-03221-4
IF: 3.1
2024-09-02
BMC Pulmonary Medicine
Abstract:With a series of clinical trials confirming the sensitivity of small cell lung cancer (SCLC) to immunotherapy, research on personalized treatment for SCLC has gained increasing attention. Currently, the most widely accepted subtype of SCLC is based on the expression levels of Achaete-Scute Family BHLH Transcription Factor 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), and POU class 2 homeobox 3 (POU2F3). However, real-world studies on this classification remain limited.
respiratory system
What problem does this paper attempt to address?